Future oncology最新文献_第4页

Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer. 鲁比丁二线单药治疗小细胞肺癌的实际应用、有效性和安全性。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/14796694.2025.2499441

Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole

{"title":"Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer.","authors":"Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole","doi":"10.1080/14796694.2025.2499441","DOIUrl":"10.1080/14796694.2025.2499441","url":null,"abstract":"Aim: Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy.Patients & methods: US-based electronic medical data from Flatiron Health (01/01/2013-03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.Results: Before PS-weighting, median (95% confidence interval [CI]) real-world progression-free survival (rwPFS) was 2.46 months (2.07-2.73), and real-world response rate (rwRR) was 27.5% (23.1-32.4) in 374 eligible lurbinectedin-treated patients. After PS-weighting, median rwPFS was 2.73 months (2.33-3.32) and 2.53 months (2.23-2.99) in 291 lurbinectedin-treated patients and 261 OST-treated patients, respectively; rwRR was 30.9% and 31.8% (relative risk, 0.97). Lurbinectedin demonstrated numerically improved median rwPFS (3.61 versus 3.02 months) and rwRR (38.7% versus 36.1%) versus OST in patients with CTFI ≥90 days but not in patients with CTFI <90 days (2.00 months both; 20.5% versus 26.1%). Lurbinectedin-treated patients reported less grade ≥3 thrombocytopenia (11.7%) and anemia (6.5%) versus OST (27.2% and 20.3%, respectively); prevalence by CTFI status were similar.Conclusion: Lurbinectedin demonstrated comparable real-world effectiveness with OST with a favorable safety profile; however, these findings are limited by small sample size.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1675-1685"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary. loncastuximab tesirine后嵌合抗原受体t细胞治疗大b细胞淋巴瘤的实际治疗：一个简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.1080/14796694.2025.2492543

Mehdi Hamadani, Melanie Lucero, Jakob D DeVos, Lei Chen

引用次数: 0

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. EXCALIBER-RRMM：伊伯度胺、达拉单抗和地塞米松治疗复发/难治性多发性骨髓瘤的III期临床试验。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-10 DOI: 10.1080/14796694.2025.2501920

Sagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, Paul G Richardson, Hang Quach, Paula Rodríguez-Otero, Paulo Maciag, Kevin Hong, Michael Amatangelo, Min Chen, Niels W C J van de Donk

{"title":"EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.","authors":"Sagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, Paul G Richardson, Hang Quach, Paula Rodríguez-Otero, Paulo Maciag, Kevin Hong, Michael Amatangelo, Min Chen, Niels W C J van de Donk","doi":"10.1080/14796694.2025.2501920","DOIUrl":"10.1080/14796694.2025.2501920","url":null,"abstract":"Multiple myeloma (MM) is a plasma cell neoplasm that stems from the malignant transformation of clonal plasma cells. It is characterized by multiple periods of remission and relapse requiring multiple lines of therapy, with response to treatment and survival decreasing with each successive relapse. To achieve deep and durable responses in relapsed/refractory MM (RRMM), novel treatments are required. Iberdomide (IBER), an oral CELMoD™ agent, is associated with greater tumoricidal and immune-stimulatory effects than immunomodulatory drugs (IMiDs®). IBER has been shown to have synergy with dexamethasone (DEX) and daratumumab (DARA) in vitro. In a phase I/II trial, IBER in combination with DARA and DEX (IberDd) was well tolerated and demonstrated promising preliminary efficacy in patients with heavily pretreated RRMM, including patients refractory to IMiD agents, DARA, and proteasome inhibitors. EXCALIBER-RRMM is a unique confirmatory phase III trial that incorporates a 2-stage seamless design to firstly address dose optimization of IberDd, and secondly, to compare the efficacy and safety of the selected IberDd dose with DARA, bortezomib, and DEX in patients with early-line (1 or 2 prior lines of therapy) RRMM.Clinical trial registration: www.clinicaltrials.gov identifier is NCT04975997.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1761-1769"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory'. 《肺科医生和胸外科医生对少转移性疾病的看法：治愈率、治疗方法和疾病轨迹》。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14796694.2025.2504786

Damla Azaklı, Inanc Yazici, Aysegul Erinc, Celal Satici

{"title":"'Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory'.","authors":"Damla Azaklı, Inanc Yazici, Aysegul Erinc, Celal Satici","doi":"10.1080/14796694.2025.2504786","DOIUrl":"10.1080/14796694.2025.2504786","url":null,"abstract":"Background: Oligometastatic disease (OMD) is defined by a limited number of metastases, affecting treatment strategies and prognosis. This study evaluates the perspectives of pulmonologists and thoracic surgeons on the curability, treatment approaches, and disease trajectory of synchronous OMD, oligorecurrence, and oligoprogression.Methods: A survey was conducted among pulmonologists, thoracic surgeons, and trainees at Yedikule Chest Disease and Thoracic Surgery Research and Training Hospital. Participants provided views on OMD's curability, treatment preferences, and confidence in discussing prognosis using Likert scales. Data were analyzed using descriptive statistics and comparative methods.Results: Of 160 contacted participants, 60 (37.5%) completed the survey. Most respondents (86.6%) regarded synchronous OMD as curable, with 65% for oligorecurrence and only 23.4% for oligoprogression. Confidence in understanding synchronous OMD's trajectory significantly differed, with attending physicians at 67.9% versus trainees at 43.8% (p < 0.05). Thoracic surgeons had higher confidence in oligorecurrence (88.3%) than pulmonologists (46%, p < 0.05). A preference for combined systemic and local therapies was noted: 73.3% for synchronous OMD, 75% for oligorecurrence, and 78.4% for oligoprogression.Conclusion: The study reveals diverse perspectives on OMD, highlighting the need for multidisciplinary collaboration and ongoing education to improve understanding and management of the disease.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1849-1857"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study. BEACON研究中BRAF v600e突变型结直肠癌患者肿瘤分子变化的简明语言总结

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1080/14796694.2025.2498880

Scott Kopetz, Danielle A Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Hedieh Saffari, Xiaosong Zhang, Phineas Hamilton, Tao Xie, Rona Yaeger, Josep Tabernero

引用次数: 0

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study. 在嵌合抗原受体t细胞治疗弥漫性大b细胞淋巴瘤后，loncastuximab tesirine的疗效如何？对真实世界证据研究的简单语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-29 DOI: 10.1080/14796694.2025.2504802

Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen

引用次数: 0

Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma. 健康的社会决定因素对多发性骨髓瘤治疗模式和结果的影响

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14796694.2025.2498878

Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen

{"title":"Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.","authors":"Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen","doi":"10.1080/14796694.2025.2498878","DOIUrl":"10.1080/14796694.2025.2498878","url":null,"abstract":"Aims: Evaluate treatment and outcomes by social determinants of health (SDoH) in multiple myeloma (MM), which are important for improving care and outcomes.Methods: This was a retrospective study of real-world patients enrolled in a US insurance claims database (MM diagnosis, July 2018-December 2022) with linkage to a SDoH database, supplemented with mortality, provider affiliation (academic/community), and socioeconomically disadvantaged area databases. Treatment and outcomes were evaluated across SDoH domains: race/ethnicity, education level, transportation access, food insecurity, risky health behaviors, living in disadvantaged areas, healthcare needs, and ease of healthcare-systems engagement.Results: The study included 4768 patients (2295 and 2731 with care-setting and treatment data); median follow-up, 584 days. Patients treated in academic versus community settings were less likely to be food insecure and live in disadvantaged areas and had lower healthcare needs. Stem cell transplant was more common in White versus non-White patients, those with low versus high food insecurity and healthcare needs, and high versus low ease of healthcare-systems engagement. In multivariable analysis, high versus low disadvantaged areas (HR = 1.75) and medium versus low food insecurity (HR = 1.80) were associated with shorter overall survival.Conclusions: These findings indicate a need for improved access to care in the broader MM population.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1663-1673"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC. 雄激素受体信号抑制剂作为一线治疗mCRPC的长期疗效的预后因素。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1080/14796694.2025.2497749

Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero

{"title":"Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.","authors":"Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero","doi":"10.1080/14796694.2025.2497749","DOIUrl":"10.1080/14796694.2025.2497749","url":null,"abstract":"Aim: Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.Methods: We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.Results: We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (p < 0.0001), longer time to mCRPC (p < 0.0001), higher baseline levels of hemoglobin (p = 0.007), lower baseline PSA levels (p = 0.03), longer PSA doubling time (p = 0.03), low number of bone metastases (p = 0.01), and receivedenzalutamide (p = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).Conclusions: Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1647-1653"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy. 基于permaar的心理干预及预测性护理在恶性肿瘤患者化疗后的效果。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1080/14796694.2025.2497257

Xiuying Hu, Qiuyue Li, Liying Tang

{"title":"Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy.","authors":"Xiuying Hu, Qiuyue Li, Liying Tang","doi":"10.1080/14796694.2025.2497257","DOIUrl":"10.1080/14796694.2025.2497257","url":null,"abstract":"Background: Alleviating the toxic and adverse reactions associated with chemotherapy is crucial for improving patient outcomes. This study aimed to assess the impacts of positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) model-based psychological interventions and predictive chemotherapy reaction nursing on patients with malignant tumors following chemotherapy.Research design and methods: The control group (n = 43) received conventional care, while the observation group (n = 43) received psychological intervention based on PERMA model alongside predictive nursing care. Chemotherapy-induced toxicity and side effects, fatigue levels, coping mode, psychological status, and quality of life were assessed.Results: Compared to the control group, the observation group exhibited a lower incidence of gastrointestinal adverse reactions, myelosuppression, alopecia, and oral ulcers (p < 0.05), reduced behavioral, cognitive, somatic, and emotional fatigue (p < 0.001), lower scores in avoidance and yielding coping styles (p < 0.001), higher scores in confrontation coding mode (p = 0.056), improved quality of life, and better outcomes in anxiety, depression, and overall psychological state of patients (p < 0.001).Conclusion: PERMA model-based psychological interventions and predictive chemotherapy reaction nursing interventions effectively reduce the incidence of chemotherapy-induced toxicity, alleviate fatigue, enhance quality of life, and improve psychological well-being in cancer patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1639-1645"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access. 克服障碍的先进生物分子技术，告知治疗实体瘤：路线图获取。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/14796694.2025.2501523

Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger

{"title":"Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.","authors":"Jesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, Bernard Avouac, Ahmad Awada, Luis de la Cruz-Merino, Åslaug Helland, Ulrik Lassen, Pierre Laurent-Puig, Nicola Normanno, Kristoffer Rohrberg, Julien Taieb, Albrecht Stenzinger","doi":"10.1080/14796694.2025.2501523","DOIUrl":"10.1080/14796694.2025.2501523","url":null,"abstract":"The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a \"roadmap to access\" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1745-1752"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0